Do you experience Refractory Chronic Cough?
This clinical research study is looking at the safety and effectiveness of an investigational medication option for people suffering from high 24-hour cough frequency with refractory chronic cough (including unexplained chronic cough).
The primary efficacy objective is to assess the effect of BLU-5937 on 24-hour cough frequency in adults with refractory chronic cough (including unexplained chronic cough) at 24 weeks.
Would you like to take part?
As a volunteer in a research study, you’ll receive study-related medical care from the study doctor and regular follow up of your condition to monitor the safety and effectiveness of the care you’ll receive. Study volunteers are an important part of moving medical care forward.
You may qualify to participate in this study if you:
- Are capable of giving signed informed consent
- Have experienced refractory chronic cough (including unexplained chronic cough) for at least one year
- Are a woman of child-bearing potential: must use a highly effective contraception method during the study and for at least 14 days after the last dose
You may not qualify to participate in this study if you:
- Are a current smoker/vaper (all forms of smoking and inhaled substances, including, cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with >20 pack-year smoking history
- Have a diagnosis of chronic obstructive pulmonary disease, bronchiectasis, chronic bronchitis, cystic fibrosis, pulmonary sarcoidosis, idiopathic pulmonary fibrosis, uncontrolled asthma, or other significant or progressive airway/respiratory disorder that might affect cough based on clinician assessment
- Have had a respiratory tract infection within 4 weeks before screening
- Have laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening
- Have a history of malignancy in the last 5 years
- Have a history of alcohol or drug abuse within the last 3 years
- Have had a positive serologic test for human immunodeficiency virus (HIV), hepatitis B virus surface antigen, or hepatitis C virus.
- Have previously participated in a BLU-5937 trial
There are other eligibility requirements that the study doctor will review. Only the study doctor can finally determine whether you are eligible to participate in the study or not.
